Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Weather
5 NC counties are under alert, including Johnston County.
Program
Friday at 6 on WRAL: How much does your county spend on education? WRAL Investigates which counties are prioritizing your children.
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Gilead Sciences, Inc.
< Previous
1
2
3
4
5
6
7
8
9
Next >
Gilead Sciences Announces Expiration of Hart-Scott-Rodino Waiting Period for CymaBay Tender Offer
March 11, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Biktarvy® Demonstrates High Rates of Viral Suppression in People With HIV and Comorbidities
March 06, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead and Merck Announce Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24
March 06, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
MRK
Gilead and Merus Announce Collaboration to Discover Novel Antibody-Based Trispecific T-Cell Engagers
March 06, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
MRUS
New Real-World Data Further Support the Use of Veklury® (Remdesivir) for People Hospitalized With COVID-19
March 05, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead’s Innovative HIV Treatment Research Pipeline Aims to Address Unmet Needs and Advance Public Health
March 05, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead Announces Funding Initiative to Support HIV Prevention, Anti-Stigma and Health Equity Efforts for Black Cisgender and Transgender Women and Girls in the U.S.
February 27, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
U.S. FDA Approves Expanded Indication for Gilead’s Biktarvy® to Treat People with HIV with Suppressed Viral Loads, Pre-existing Resistance
February 26, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead to Present Late-Breaking Data and Real-World Evidence Highlighting Innovative Antiviral Portfolio and Research Pipeline at CROI 2024
February 26, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead Sciences to Present at Upcoming Investor Conferences
February 20, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead Sciences Expands Liver Portfolio With Acquisition of CymaBay Therapeutics
February 12, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
CBAY
GILD
Gilead Named One of America’s Most JUST Companies by JUST Capital and CNBC
February 09, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead Sciences Announces 2.7 Percent Increase in First Quarter 2024 Dividend
February 06, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead Sciences Announces Fourth Quarter and Full Year 2023 Financial Results
February 06, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Ted Love, MD, Joins Gilead Sciences’ Board of Directors
February 01, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Kite Receives U.S. FDA Approval of Manufacturing Process Change Resulting in Reduced Median Turnaround Time for Yescarta® CAR T-cell Therapy
January 30, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead Sciences to Release Fourth Quarter & Full Year 2023 Financial Results on Tuesday, February 6, 2024
January 23, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead Provides Update on Phase 3 EVOKE-01 Study
January 22, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead Sciences to Present at Upcoming Investor Conference
December 21, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
U.S. FDA Approves Label Update for Kite’s Yescarta® CAR T-Cell Therapy to Include Overall Survival Data
December 21, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead and Compugen Announce Exclusive License Agreement for Novel Pre-Clinical Immunotherapy Program
December 19, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
CGEN
GILD
Analyses of Kite’s Yescarta® CAR T-Cell Therapy Support Curative Potential in Patients With Non-Hodgkin Lymphomas
December 11, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
New Analyses Presented at ASH 2023 Support the Potential Long-Term Response and Safety of Kite’s Tecartus® in Patients With Aggressive Blood Cancers
December 11, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Long-Term Data for Kite’s Yescarta® CAR T-Cell Therapy Presented at ASH 2023 Demonstrate High Rate of Durable Response in Patients With High-Risk Large B-Cell Lymphoma
December 11, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead Named to Dow Jones Sustainability World Index for Third Consecutive Year
December 11, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead’s Leadership in Metastatic Breast Cancer Showcased With New Trodelvy Data at San Antonio Breast Cancer Symposium 2023
November 30, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Kite and Arcellx Announce Expansion in Strategic Partnership
November 15, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
ACLX
GILD
Gilead Sciences to Present at Upcoming Investor Conferences
November 08, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead Sciences Announces Third Quarter 2023 Financial Results
November 07, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead and Arcus Announce New Data Showing Encouraging Clinical Activity of Anti-TIGIT Domvanalimab-Containing Regimen as First-line Treatment for Upper GI Cancers
November 06, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
RCUS
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.